Compare AbbVie Inc (ABBV) vs MasterCard Inc (MA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs MasterCard Inc — how do they compare? AbbVie Inc trades at $253.71 (market cap $449.91B), while MasterCard Inc trades at $519.65 (market cap $469.73B). The key difference: AbbVie Inc and MasterCard Inc are close in size by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MA | |
|---|---|---|
Market Cap | $449.91B | $469.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $598.96 |
52-Week Low | $184.85 | $471.55 |
Enterprise Value | $513.38B | $480.47B |
Dividend Yield | 2.72% | 0.65% |
Volume | — | 4,635,698 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Mastercard (MA) trades at $517.78, down 2.87% on the day, amid a bullish technical outlook and strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $32.79B and net income of $14.97B, supported by high profitability margins. Recent earnings beats and a consensus analyst price target of $637.67 highlight positive sentiment, though elevated valuation ratios like a P/E of 30.77 warrant caution.
Outlook remains favorable with continued earnings growth and institutional accumulation, but risks include competitive disruption from new payment technologies and high valuation multiples. The stock's current price near key support at $514 suggests potential for rebound if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
